Built with thought leaders from Seattle Genetics, Precision Biosciences and Kite Pharma, the inaugural industry-focused BCMA Targeted Therapies Summit will share the field’s cutting-edge and ...

While teclistamab looks on course to be the first BCMA-targeting bispecific antibody to reach the market, Pfizer is hot on J&J's heels with its BCMAxCD3 drug elranatamab and reported phase 2 data ...

Introduction: Idecabtagene vicleucel (Ide-Cel) and ciltacabtagene autoleucel (Cilta-cel) are novel CAR-T therapies targeting B-cell maturation antigen (BCMA) and approved for relapsed and refractory ...

Carvykti followed Bristol Myers Squibb and 2Seventy bio’s Abecma onto the market. Like Abecma, it is a CAR-T therapy targeted to a protein called BCMA that’s commonly found on diseased multiple ...

These doses included 1 mg/kg in the MC38-GPRC5D syngeneic model and 0.3 mg/kg in the NCI-H929 xenograft model. Toxicology studies have also previously revealed that repeated intravenous doses of ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...